Literature DB >> 2554875

Studies on the mechanism of action of the bipyridine milrinone on the heart.

A E Farah1, C J Frangakis.   

Abstract

Milrinone is a positive inotropic and vasodilator agent when tested in experimental animals and in human heart-failure patients. It is generally believed that milrinone acts by inhibiting phosphodiesterase IV, thus increasing cyclic AMP, [Ca++]i and cardiac contractile force and relaxation. Maximal force produced by milrinone is greater when single-dose response curves are compared to cumulative dose-response curves. In vitro, milrinone produces a tachyphylaxis, the extent of which is both dose- and time-dependent. Recovery of tachyphylaxis is both dose- and time-dependent and is not influenced by inhibitors of protein or RNA synthesis. There is a specific cross-tachyphylaxis between milrinone and amrinone, theophylline, papaverine, and Bay K8644. This tachyphylaxis may explain the low maximal contractile response of the cumulative dose-response observed in isolated tissues. Milrinone increased cyclic AMP in dog and guinea pig cardiac muscle. As previously shown by Endoh et al., milrinone in low doses produced a biphasic effect on cyclic AMP. The early increase (first 60-70 s) in cyclic AMP shows a good correlation with contractile force changes. If cyclic AMP is determined at maximal contractile force this correlation was poor. Here we also present instances where the increase in cyclic AMP after milrinone (determined at maximal effect) does not correlate with the contractile response. The cross-tachyphylaxis of milrinone with Bay K8644 suggests that milrinone has an action on the sarcolemmal Ca++ channels. Bay K8644 suppresses the positive inotropic effect of catecholamines by 50%, but not the cyclic AMP response. The inotropic effect of milrinone, in contrast to norepinephrine is highly sensitive to [Ca++]0, stimulation rate, and [K+]0. In this respect milrinone behaves more like Bay K8644. We postulate that the main inotropic action of milrinone is due to a sarcolemmal effect. The early cyclic AMP production described could be in the sarcolemmal compartment and this may explain some of the similarities of milrinone's actions with those of Bay K8644. The tachyphylaxis observed with the inotropic effect of milrinone does not extend to the decreases in relaxation time. This and other findings to be discussed suggest that the positive inotropic and reduction in relaxation time by milrinone depend on different mechanisms, possibly through differential compartmentalization of cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554875     DOI: 10.1007/BF02650349

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  52 in total

Review 1.  Cyclic AMP and contractile activity in heart.

Authors:  R W Tsien
Journal:  Adv Cyclic Nucleotide Res       Date:  1977

Review 2.  Kinetic properties of the plasma membrane Na+-H+ exchanger.

Authors:  P S Aronson
Journal:  Annu Rev Physiol       Date:  1985       Impact factor: 19.318

Review 3.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

4.  Amiloride selectively blocks the low threshold (T) calcium channel.

Authors:  C M Tang; F Presser; M Morad
Journal:  Science       Date:  1988-04-08       Impact factor: 47.728

5.  Phosphorylation of cardiac sarcolemma proteins by the calcium-activated phospholipid-dependent protein kinase.

Authors:  Y Iwasa; M M Hosey
Journal:  J Biol Chem       Date:  1984-01-10       Impact factor: 5.157

6.  Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.

Authors:  P Mushlin; R C Boerth; J N Wells
Journal:  Mol Pharmacol       Date:  1981-07       Impact factor: 4.436

7.  Evidence for two separated Ca2+ pathways in smooth muscle plasmalemma.

Authors:  K D Meisheri; O Hwang; C van Breemen
Journal:  J Membr Biol       Date:  1981-03-15       Impact factor: 1.843

8.  Effects of amrinone and milrinone on calcium influx into the myocardium.

Authors:  J L Sutko; J L Kenyon; J P Reeves
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

9.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

10.  The effect of extracellular Ca2+ and related ions on the cardiac action of milrinone.

Authors:  A E Farah; P C Canniff; R G Bentley; C J Frangakis
Journal:  J Cardiovasc Pharmacol       Date:  1988-05       Impact factor: 3.105

View more
  5 in total

1.  The effects of milrinone in the neonatal pig heart.

Authors:  N T Ross-Ascuitto; R J Ascuitto; D Ramage; K H McDonough
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

2.  A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium.

Authors:  Carmen C Sucharov; Stephanie J Nakano; Dobromir Slavov; Jessica A Schwisow; Erin Rodriguez; Karin Nunley; Allen Medway; Natalie Stafford; Penny Nelson; Timothy A McKinsey; Matthew Movsesian; Wayne Minobe; Ian A Carroll; Matthew R G Taylor; Michael R Bristow
Journal:  J Am Coll Cardiol       Date:  2019-03-19       Impact factor: 24.094

Review 3.  Phosphodiesterase III inhibitors: long-term risks and short-term benefits.

Authors:  J M Cruickshank
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

Review 4.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

5.  Association of preoperative duration of inotropy on prevalence of right ventricular failure following LVAD implantation.

Authors:  Mina M Benjamin; Sakthi Sundararajan; Samian Sulaiman; Bryan Miles; Rebekah J Walker; Lucian Durham; Takushi Kohmoto; David L Joyce; David Ishizawar; Nunzio Gaglianello; Asim Mohammed
Journal:  ESC Heart Fail       Date:  2020-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.